Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C.

Gastroenterology. 2019 Jul;157(1):227-241.e7. doi: 10.1053/j.gastro.2019.03.044. Epub 2019 Mar 28.

PMID:
30930022
2.

Real life experiences in HCV management in 2018.

Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL.

Expert Rev Anti Infect Ther. 2019 Feb;17(2):117-128. doi: 10.1080/14787210.2019.1563755. Epub 2019 Jan 15. Review.

PMID:
30582384
3.

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.

Lampertico P, Brunetto MR, Craxì A, Gaeta GB, Rizzetto M, Rozzi A, Colombo M; HERMES Study Group.

J Viral Hepat. 2019 Jan;26(1):118-125. doi: 10.1111/jvh.12999. Epub 2018 Dec 11.

PMID:
30187599
4.

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.

Wei L, Wedemeyer H, Liaw YF, Chan HL, Piratvisuth T, Marcellin P, Jia J, Tan D, Chow WC, Brunetto MR, Diago M, Gurel S, Morozov V, He H, Zhu Y, Wat C, Surujbally B, Thompson AJ.

PLoS One. 2018 Jul 17;13(7):e0199198. doi: 10.1371/journal.pone.0199198. eCollection 2018.

5.

Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection.

Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL.

Clin Gastroenterol Hepatol. 2018 Jun 20. pii: S1542-3565(18)30633-5. doi: 10.1016/j.cgh.2018.06.023. [Epub ahead of print]

PMID:
29933096
6.

Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Kondili LA, Robbins S, Blach S, Gamkrelidze I, Zignego AL, Brunetto MR, Raimondo G, Taliani G, Iannone A, Russo FP, Santantonio TA, Zuin M, Chessa L, Blanc P, Puoti M, Vinci M, Erne EM, Strazzabosco M, Massari M, Lampertico P, Rumi MG, Federico A, Orlandini A, Ciancio A, Borgia G, Andreone P, Caporaso N, Persico M, Ieluzzi D, Madonia S, Gori A, Gasbarrini A, Coppola C, Brancaccio G, Andriulli A, Quaranta MG, Montilla S, Razavi H, Melazzini M, Vella S, Craxì A; PITER Collaborating Group.

Liver Int. 2018 Dec;38(12):2190-2198. doi: 10.1111/liv.13901. Epub 2018 Aug 10.

7.

Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study.

Stasi C, Silvestri C, Berni R, Brunetto MR, Zignego AL, Orsini C, Milani S, Ricciardi L, De Luca A, Blanc P, Nencioni C, Aquilini D, Bartoloni A, Bresci G, Marchi S, Filipponi F, Colombatto P, Forte P, Galli A, Luchi S, Chigiotti S, Nerli A, Corti G, Sacco R, Carrai P, Ricchiuti A, Giusti M, Almi P, Cozzi A, Carloppi S, Laffi G, Voller F, Cipriani F.

World J Hepatol. 2018 May 27;10(5):409-416. doi: 10.4254/wjh.v10.i5.409.

8.

Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging.

Di Lascio N, Avigo C, Salvati A, Martini N, Ragucci M, Monti S, Prinster A, Chiappino D, Mancini M, D'Elia D, Ghiadoni L, Bonino F, Brunetto MR, Faita F.

Ultrasound Med Biol. 2018 Aug;44(8):1585-1596. doi: 10.1016/j.ultrasmedbio.2018.03.011. Epub 2018 May 4.

PMID:
29735312
9.

High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.

Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S.

Aliment Pharmacol Ther. 2018 Jun;47(12):1705-1712. doi: 10.1111/apt.14685. Epub 2018 May 3.

PMID:
29722439
10.

Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection.

Ricco G, Popa DC, Cavallone D, Iacob S, Salvati A, Tabacelia D, Oliveri F, Mascolo G, Bonino F, Yuan Q, Xia NS, Gheorghe L, Brunetto MR.

J Viral Hepat. 2018 Aug;25(8):911-919. doi: 10.1111/jvh.12895. Epub 2018 May 17.

PMID:
29577518
11.

Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research.

Mancini M, Summers P, Faita F, Brunetto MR, Callea F, De Nicola A, Di Lascio N, Farinati F, Gastaldelli A, Gridelli B, Mirabelli P, Neri E, Salvadori PA, Rebelos E, Tiribelli C, Valenti L, Salvatore M, Bonino F.

World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231. Review.

12.

HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood.

Colombatto P, Barbera C, Bortolotti F, Maina AM, Moriconi F, Cavallone D, Calvo P, Oliveri F, Bonino F, Brunetto MR.

J Med Virol. 2018 Jul;90(7):1232-1239. doi: 10.1002/jmv.25068. Epub 2018 Apr 23.

PMID:
29488227
13.

TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C.

Gastroenterology. 2018 May;154(6):1764-1777.e7. doi: 10.1053/j.gastro.2018.01.030. Epub 2018 Jan 31.

PMID:
29378197
14.

Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M.

PLoS One. 2018 Jan 2;13(1):e0190803. doi: 10.1371/journal.pone.0190803. eCollection 2018.

15.

Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.

Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR.

Cancer Biomark. 2018 Feb 14;21(3):603-612. doi: 10.3233/CBM-170551.

PMID:
29278878
16.

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.

Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ.

J Hepatol. 2018 Mar;68(3):431-440. doi: 10.1016/j.jhep.2017.10.027. Epub 2017 Dec 11.

PMID:
29104121
17.

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.

Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG.

PLoS One. 2017 Oct 4;12(10):e0185728. doi: 10.1371/journal.pone.0185728. eCollection 2017.

18.

Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.

Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S.

Liver Int. 2018 May;38(5):821-833. doi: 10.1111/liv.13596. Epub 2017 Oct 12.

19.

Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.

Kondili LA, Romano F, Rolli FR, Ruggeri M, Rosato S, Brunetto MR, Zignego AL, Ciancio A, Di Leo A, Raimondo G, Ferrari C, Taliani G, Borgia G, Santantonio TA, Blanc P, Gaeta GB, Gasbarrini A, Chessa L, Erne EM, Villa E, Ieluzzi D, Russo FP, Andreone P, Vinci M, Coppola C, Chemello L, Madonia S, Verucchi G, Persico M, Zuin M, Puoti M, Alberti A, Nardone G, Massari M, Montalto G, Foti G, Rumi MG, Quaranta MG, Cicchetti A, Craxì A, Vella S; PITER Collaborating Group.

Hepatology. 2017 Dec;66(6):1814-1825. doi: 10.1002/hep.29399. Epub 2017 Oct 30.

20.

Genome-Wide Comparison of Next-Generation Sequencing and qPCR Platforms for microRNA Profiling in Serum.

Blondal T, Brunetto MR, Cavallone D, Mikkelsen M, Thorsen M, Mang Y, Pinheiro H, Bonino F, Mouritzen P.

Methods Mol Biol. 2017;1580:21-44. doi: 10.1007/978-1-4939-6866-4_3.

PMID:
28439824
21.

Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.

Oliveri F, Surace L, Cavallone D, Colombatto P, Ricco G, Salvati N, Coco B, Romagnoli V, Gattai R, Salvati A, Moriconi F, Yuan Q, Bonino F, Brunetto MR.

Liver Int. 2017 Nov;37(11):1622-1631. doi: 10.1111/liv.13416. Epub 2017 Apr 18.

PMID:
28296013
22.

Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.

Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M.

PLoS One. 2017 Feb 28;12(2):e0172159. doi: 10.1371/journal.pone.0172159. eCollection 2017. Erratum in: PLoS One. 2018 Jan 2;13(1):e0190803.

23.

New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases.

Ricco G, Bonino F, Lanza M, Scatena F, Alfieri CM, Messa P, Marchisio E, Mascolo G, Romanò L, Galli C, Li TC, Wakita T, Miyamura T, Brunetto MR.

Dig Liver Dis. 2016 May;48(5):536-541. doi: 10.1016/j.dld.2016.01.007. Epub 2016 Feb 10.

PMID:
26936342
24.

Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.

Brouwer WP, Chan HL, Brunetto MR, Martinot-Peignoux M, Arends P, Cornberg M, Cherubini B, Thompson AJ, Liaw YF, Marcellin P, Janssen HL, Hansen BE; Good Practice in using HBsAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group).

Clin Gastroenterol Hepatol. 2016 Oct;14(10):1481-1489.e5. doi: 10.1016/j.cgh.2016.01.019. Epub 2016 Feb 10.

PMID:
26872398
25.

Transmission FTIR derivative spectroscopy for estimation of furosemide in raw material and tablet dosage form.

Gallignani M, Rondón RA, Ovalles JF, Brunetto MR.

Acta Pharm Sin B. 2014 Oct;4(5):376-83. doi: 10.1016/j.apsb.2014.06.013. Epub 2014 Aug 8.

26.

Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.

Messori A, Brunetto MR, De Luca A, Zignego AL.

Dig Liver Dis. 2015 Nov;47(11):988-9. doi: 10.1016/j.dld.2015.06.012. Epub 2015 Jul 2. No abstract available.

PMID:
26205830
27.

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.

Yuan Q, Song LW, Cavallone D, Moriconi F, Cherubini B, Colombatto P, Oliveri F, Coco BA, Ricco G, Bonino F, Shih JW, Xia NS, Brunetto MR.

PLoS One. 2015 Jun 26;10(6):e0130209. doi: 10.1371/journal.pone.0130209. eCollection 2015.

28.

Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.

Brunetto MR, De Luca A, Messori A, Zignego AL.

BMJ. 2015 Jun 24;350:h3363. doi: 10.1136/bmj.h3363. No abstract available.

PMID:
26108546
29.

A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C.

Iannazzo S, Colombatto P, Ricco G, Oliveri F, Bonino F, Brunetto MR.

Dig Liver Dis. 2015 Mar;47(3):249-54. doi: 10.1016/j.dld.2014.12.008. Epub 2014 Dec 18.

PMID:
25575431
30.

Cost-Effectiveness Analysis Of A Personalized Therapy For Genotype 1, Naive, Chronic Hepatitis C Patients In Italy.

Iannazzo S, Colombatto P, Bonino F, Brunetto MR.

Value Health. 2014 Nov;17(7):A366. doi: 10.1016/j.jval.2014.08.819. Epub 2014 Oct 26. No abstract available.

31.

A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.

Brunetto MR, Cavallone D, Oliveri F, Moriconi F, Colombatto P, Coco B, Ciccorossi P, Rastelli C, Romagnoli V, Cherubini B, Teilum MW, Blondal T, Bonino F.

PLoS One. 2014 Oct 28;9(10):e110782. doi: 10.1371/journal.pone.0110782. eCollection 2014.

32.

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.

PMID:
25311593
33.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2015 Jun;64(6):948-56. doi: 10.1136/gutjnl-2014-307498. Epub 2014 Jul 30.

PMID:
25080450
34.

Interferon therapy of chronic hepatitis B.

Brunetto MR, Bonino F.

Intervirology. 2014;57(3-4):163-70. doi: 10.1159/000360941. Epub 2014 Jul 15.

35.

HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.

Colombatto P, Brunetto MR, Maina AM, Romagnoli V, Almasio P, Rumi MG, Ascione A, Pinzello G, Mondelli M, Muratori L, Rappuoli R, Rosa D, Houghton M, Abrignani S, Bonino F.

J Viral Hepat. 2014 Jul;21(7):458-65. doi: 10.1111/jvh.12163. Epub 2013 Aug 27. Erratum in: J Viral Hepat. 2014 Oct;21(10):751.

36.

Reagent-free determination of amikacin content in amikacin sulfate injections by FTIR derivative spectroscopy in a continuous flow system.

Ovalles JF, Gallignani M, Brunetto MR, Rondón RA, Ayala C.

J Pharm Anal. 2014 Apr;4(2):125-131. doi: 10.1016/j.jpha.2013.08.001. Epub 2013 Aug 14.

37.

Chance and necessity of simultaneous HBsAg and anti-HBs detection in the serum of chronic HBsAg carriers.

Brunetto MR.

J Hepatol. 2014 Mar;60(3):473-5. doi: 10.1016/j.jhep.2013.12.001. Epub 2013 Dec 7. No abstract available.

38.

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.

J Hepatol. 2013 Dec;59(6):1153-9. doi: 10.1016/j.jhep.2013.07.017. Epub 2013 Jul 18.

PMID:
23872601
39.

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients.

Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR.

Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23.

40.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.

PMID:
23486701
41.

Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line.

Cavallone D, Moriconi F, Colombatto P, Oliveri F, Bonino F, Brunetto MR.

J Virol Methods. 2013 Apr;189(1):110-7. doi: 10.1016/j.jviromet.2013.01.012. Epub 2013 Feb 4.

PMID:
23391821
42.

Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs.

Novellino L, Rossi RL, Bonino F, Cavallone D, Abrignani S, Pagani M, Brunetto MR.

PLoS One. 2012;7(3):e31952. doi: 10.1371/journal.pone.0031952. Epub 2012 Mar 28.

43.

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years.

Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T.

J Hepatol. 2012 Jun;56(6):1254-8. doi: 10.1016/j.jhep.2012.01.022. Epub 2012 Feb 16.

PMID:
22343167
44.

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.

Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HL, Lampertico P.

J Hepatol. 2012 May;56(5):1006-11. doi: 10.1016/j.jhep.2011.12.007. Epub 2012 Jan 13.

PMID:
22245886
45.

Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?

Janssen HL, Sonneveld MJ, Brunetto MR.

Gut. 2012 May;61(5):641-5. doi: 10.1136/gutjnl-2011-301096. Epub 2011 Dec 16. Review. No abstract available.

PMID:
22180061
46.

Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay.

Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirotchanakul S, Phisalprapa P, Tanwandee T, Wursthorn K, Brunetto MR, Wedemeyer H, Bonino F.

Clin Vaccine Immunol. 2011 Nov;18(11):1943-50. doi: 10.1128/CVI.05122-11. Epub 2011 Aug 31.

47.

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P.

J Hepatol. 2011 Nov;55(5):1121-31. doi: 10.1016/j.jhep.2011.06.006. Epub 2011 Jun 28. Review.

48.

Liver stiffness, a non-invasive marker of liver disease: a core study group report.

Bonino F, Arena U, Brunetto MR, Coco B, Fraquelli M, Oliveri F, Pinzani M, Prati D, Rigamonti C, Vizzuti F; Liver Stiffness Study Group 'Elastica' of the Italian Association for the Study of the Liver.

Antivir Ther. 2010;15 Suppl 3:69-78. doi: 10.3851/IMP1626.

PMID:
21041906
49.

New approaches to optimize treatment responses in chronic hepatitis B.

Brunetto MR, Lok AS.

Antivir Ther. 2010;15 Suppl 3:61-8. doi: 10.3851/IMP1625. Review.

PMID:
21041905
50.

Diagnostic markers of chronic hepatitis B infection and disease.

Bonino F, Piratvisuth T, Brunetto MR, Liaw YF.

Antivir Ther. 2010;15 Suppl 3:35-44. doi: 10.3851/IMP1622. Review.

PMID:
21041902

Supplemental Content

Loading ...
Support Center